GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » YoY EBITDA Growth

TC BioPharm (Holdings) (TC BioPharm (Holdings)) YoY EBITDA Growth : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TC BioPharm (Holdings)'s YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 0.00%.

TC BioPharm (Holdings)'s EBITDA per Share for the three months ended in Mar. 2024 was $-2.80.

TC BioPharm (Holdings) YoY EBITDA Growth Historical Data

The historical data trend for TC BioPharm (Holdings)'s YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) YoY EBITDA Growth Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- 5.54 -176.85 122.99 -116.00

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 88.41 113.88 - -

TC BioPharm (Holdings) YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TC BioPharm (Holdings)'s YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-25.725-160.824)/ | 160.824 |
=-116.00 %

TC BioPharm (Holdings)'s YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-2.795-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » YoY EBITDA Growth
Comparable Companies
XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN XKRX:068270 XBRU:UCB RPRX INCY
Traded in Other Exchanges
T0U:Germany
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
Website
https://www.tcbiopharm.com
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD